Biogen ALS Drug Showed No Benefit, O'Neill Says

Jan. 3 (Bloomberg) -- Gilmore O’Neill, vice president of clinical development at Biogen Idec Inc., talks with Bloomberg's Meg Tirrell about the company's announcement that its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New York time after saying it will end development of the medicine for ALS, also known as Lou Gehrig’s disease. (Source: Bloomberg)

Inside Commerzbank's Operational Risk
59:46 - Bloomberg Gadfly Columnist Lionel Laurent reports on the performance of Commerzbank. He speaks on "Bloomberg Markets." His opinions are his own. (Source: Bloomberg)
  • Global Banking Empires Shrink, Here's Why
  • Gilead Science's Falls Most in Almost Three Months
  • Nigerian Central Bank Raises Its Key Interest Rate